Cipher Pharmaceuticals Company Profile (NASDAQ:CPHR)

About Cipher Pharmaceuticals (NASDAQ:CPHR)

Cipher Pharmaceuticals logoCipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CPHR
  • CUSIP: N/A
  • Web:
Average Prices:
  • 50 Day Moving Avg: $2.99
  • 200 Day Moving Avg: $2.98
  • 52 Week Range: $2.55 - $6.25
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 149.51
  • P/E Growth: 0.0000
  • Net Margins: -64.97%
  • Return on Equity: -9.83%
  • Return on Assets: -4.40%
  • Debt-to-Equity Ratio: 1.22%
  • Current Ratio: 2.59%
  • Quick Ratio: 2.50%
  • Beta: 1.39

Frequently Asked Questions for Cipher Pharmaceuticals (NASDAQ:CPHR)

What is Cipher Pharmaceuticals' stock symbol?

Cipher Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPHR."

How were Cipher Pharmaceuticals' earnings last quarter?

Cipher Pharmaceuticals Inc (NASDAQ:CPHR) announced its earnings results on Thursday, May, 5th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.06. The business had revenue of $9.10 million for the quarter, compared to analyst estimates of $10.87 million. Cipher Pharmaceuticals had a negative return on equity of 9.83% and a negative net margin of 64.97%. View Cipher Pharmaceuticals' Earnings History.

Where is Cipher Pharmaceuticals' stock going? Where will Cipher Pharmaceuticals' stock price be in 2017?

2 brokerages have issued 1-year price objectives for Cipher Pharmaceuticals' stock. Their predictions range from $3.50 to $3.50. On average, they expect Cipher Pharmaceuticals' stock price to reach $3.50 in the next twelve months. View Analyst Ratings for Cipher Pharmaceuticals.

Who are some of Cipher Pharmaceuticals' key competitors?

How do I buy Cipher Pharmaceuticals stock?

Shares of Cipher Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cipher Pharmaceuticals stock cost?

One share of Cipher Pharmaceuticals stock can currently be purchased for approximately $2.99.

Analyst Ratings

Consensus Ratings for Cipher Pharmaceuticals (NASDAQ:CPHR) (?)
Ratings Breakdown: 2 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $3.50 (17.05% upside)

Analysts' Ratings History for Cipher Pharmaceuticals (NASDAQ:CPHR)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/16/2016TD SecuritiesDowngradeBuy -> Hold$7.50 -> $3.50N/AView Rating Details
8/13/2016GMP SecuritiesReiterated RatingHoldN/AView Rating Details
11/30/2015CIBCInitiated CoverageSector Outperform -> Outperform$6.20N/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for Cipher Pharmaceuticals (NASDAQ:CPHR)
Earnings by Quarter for Cipher Pharmaceuticals (NASDAQ:CPHR)
Earnings History by Quarter for Cipher Pharmaceuticals (NASDAQ:CPHR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/11/2016Q316($0.10)($0.08)$10.42 million$9.30 millionViewN/AView Earnings Details
5/5/2016Q116($0.04)($0.10)$10.87 million$9.10 millionViewN/AView Earnings Details
11/4/2015Q3 2015$0.07($0.04)$12.50 million$8.46 millionViewN/AView Earnings Details
8/14/2015Q2 2015$0.02$0.01$11.50 million$8.84 millionViewN/AView Earnings Details
5/13/2015Q115$0.17$0.10$7.88 million$9.18 millionViewN/AView Earnings Details
2/25/2015Q4 2014$0.12$0.11$6.72 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cipher Pharmaceuticals (NASDAQ:CPHR)
2017 EPS Consensus Estimate: $0.04
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.03$0.03$0.03
Q2 20171$0.01$0.01$0.01
Q3 20171$0.01$0.01$0.01
Q4 20171($0.01)($0.01)($0.01)
(Data provided by Zacks Investment Research)


Dividend History for Cipher Pharmaceuticals (NASDAQ:CPHR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Cipher Pharmaceuticals (NASDAQ:CPHR)
No insider trades for this company have been tracked by


Headline Trends for Cipher Pharmaceuticals (NASDAQ:CPHR)
Latest Headlines for Cipher Pharmaceuticals (NASDAQ:CPHR)
DateHeadline logoCipher's (CPHR) CEO Robert Tessarolo on Q1 2017 Results - Earnings Call Transcript - May 12 at 10:03 PM logoCipher Pharmaceuticals (CPHR) Receives Daily Media Impact Rating of 0.23 - May 4 at 1:13 AM logoCipher Pharmaceuticals Announces Management Change - April 7 at 9:09 AM logoCipher Pharmaceuticals Reports Q3 2016 Financial Results - April 7 at 9:09 AM logo6:30 am Cipher Pharma announces plans to voluntarily delist from Nasdaq - November 30 at 4:33 PM logoArrowhead Blunted, CERC Depressed, It's All Clear For NOVN, CPHR Leaves Nasdaq - November 30 at 9:26 AM logoCipher Pharma (CPHR) Will Delist from Nasdaq on Voluntary Basis - November 30 at 9:26 AM logoCipher Pharmaceuticals Responds to Request for Comment from IIROC - October 31 at 4:27 PM logoCipher Pharma (CPHR) Confirms It's Working with Advisor on Various Strategic Alternatives - October 31 at 4:27 PM logoNotice of Cipher Pharmaceuticals Inc. Q3 2016 Conference Call - October 27 at 4:43 PM logoCipher Pharma (CPHR) Names Stephen Lemieux as CFO - September 2 at 9:09 AM logoCipher Pharmaceuticals Reports Q2 2016 Results Highlighted by 32% Revenue Growth and $3.1 Million Cash from Operations - August 10 at 8:04 AM logoNotice of Cipher Pharmaceuticals Inc. Q2 2016 Conference Call - July 20 at 12:00 PM logoSpecial Committee of Cipher Pharmaceuticals Responds to Early Warning Report Filed by 1207407 Ontario Limited - July 6 at 10:00 AM logoCipher Pharmaceuticals to Present at Two Upcoming U.S. Investor Conferences - May 31 at 10:00 AM logoCipher Pharma (CPHR) Licenses Global Rights to Dalhousie University's Investigational Tattoo Removal Cream - May 3 at 10:44 AM logoCipher Pharma (CPHR) Licenses Global Rights to Dalhousie University's Investigational Tattoo Removal Cream - - May 2 at 11:37 AM logoCipher Pharma's (CPHR) CFO Norm Evans to Retire - April 24 at 10:28 AM logoCipher Pharma's (CPHR) CFO Norm Evans to Retire - - April 23 at 10:38 AM logoCoverage initiated on Cipher Pharma by TD Securities - April 13 at 9:07 AM logoCipher Pharma's (CPHR) Dermadexin and Pruridexin Approved in Canada - April 7 at 10:27 AM logoCipher Pharma (CPHR) Launches Actikerall in Canada - February 23 at 8:53 AM logoCipher Pharma (CPHR) Sitavig NDA Accepted for Review by Health Canada - February 18 at 8:51 AM logo7:02 am Cipher Pharma announces review acceptance by Health Canada for Sitavig - February 16 at 7:02 AM logoStoneCastle's Bruce Campbell Interviewed by The Life Sciences Report - February 4 at 1:30 PM logoCipher Pharmaceuticals Inc. (CPHR) - January 23 at 5:22 PM logoEuro Pacific Canada's Doug Loe Interviewed by The Life Sciences Report - January 15 at 9:00 AM logoSanta Brings FDA and Health Canada Approvals for New Dermatology Products - December 21 at 9:45 AM logoNotice of Cipher Pharmaceuticals Inc. Q3 2015 Conference Call - October 21 at 8:30 AM logoCipher announces settlement in patent litigation for Absorica® - October 5 at 7:00 AM logoCPHR: Product Sales Picked Up Steam in Second Quarter of 2015 - August 21 at 11:25 AM



Cipher Pharmaceuticals (CPHR) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff